|
Co-Chief Editors
Joseph Bick, M.D.
Chief Medical Officer, California Medical Facility, California Department of Corrections
Anne S. De Groot, M.D.
Director, TB/HIV Research Lab, Brown Medical School
Deputy Editors
Frederick L. Altice, M.D.
Director, HIV in Prisons Program, Yale University AIDS Program
David P. Paar, M.D.
Director, AIDS Care and Clinical Research Program, University of Texas, Medical Branch
Bethany Weaver, D.O., M.P.H.
Acting Instructor, Univ. of Washington Center for AIDS and STD Research
Renee Ridzon, M.D.
Bill & Melinda Gates Foundation
Senior Advisors
Karl Brown, M.D.
Rikers Island Jail
Ralf Jürgens
Canadian HIV/AIDS Legal Network
Joseph Paris, Ph.D., M.D.
CCHP Georgia Dept. of Corrections
Abby Dees, J.D.
CorrectHELP: Corrections HIV Education and Law Project
David Thomas, M.D., J.D.
Division of Correctional Medicine, NovaSoutheastern University College of Osteopathic Medicine
Louis C. Tripoli, M.D., F.A.C.F.E.
Correctional Medical Institute, Correctional Medical Services
Lester Wright, M.D.
New York State Department of Corrections
Associate Editors
Dean Rieger, M.D.
Indiana Department of Corrections
Josiah Rich, M.D.
Brown University School of Medicine, The Miriam Hospital
Steven F. Scheibel, M.D.
Regional Medical Director Prison Health Services, Inc.
David A. Wohl, M.D.
University of North Carolina
Michelle Gaseau
The Corrections Connection
Layout
Kimberly Backlund-Lewis
The Corrections Connection
Distribution
Screened Images Multimedia
Managing Editor
Courney E. Colton
IDCR
Faculty Disclosure
In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial Support, the faculty for this activity have been asked to complete Conflict of Interest Disclosure forms. Disclosures are listed at the end of articles. All of the individual medications discussed in this newsletter are approved for treatment of HIV and hepatitis unless otherwise indicated. For the treatment of HIV and hepatitis infection, many physicians opt to use combination antiretroviral therapy which is not addressed by the FDA.
Supporters
IDCR is grateful for the support of the following companies through unrestricted educational grants:
- Major Support: Abbott Laboratories, Boehringer Ingelheim and Roche Pharmaceuticals
- Sustaining: Pfizer Inc., Gilead Sciences Inc., GlaxoSmithKline, Merck & Co., Schering-Plough and ViroLogic.
|
